Given that the formulation is not custom-tailored to pancreatic cancer, as with active targeted to cell surface receptors found only in pancreatic cancer, we envision the P(Glu-co-Lys)1:5-GNR being a class solution for a wide range of tumors independent of histology or genetic makeup. This evidence concerns the gene CD177 and pancreatic neoplasm.